Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 9,654 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Human Clear all
Completed Phase 2 Interventional Results available

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT01720173
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Dalantercept, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
40
States / cities
Fort Collins, Colorado • Hartford, Connecticut • New Britain, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 28, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

NCT03981822
View directory record Official record
Conditions
Condylomata Acuminata, Papillomavirus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Sexually Transmitted Diseases, Viral, Sexually Transmitted Diseases, Warts
Interventions
VP-102 and applicator, Placebo
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Plainfield, Indiana • Baton Rouge, Louisiana • Clarkston, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 28, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

NCT01275131
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin aspart, Recombinant human hyaluronidase PH20 (rHuPH20)
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 28, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults

NCT02609945
View directory record Official record
Conditions
Migraine
Interventions
zolmitriptan, CVT-427 (zolmitriptan inhalation powder),
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 28, 2026, 4:15 PM EDT
Recruiting Not applicable Interventional

Virtual Home-based Exercise Intervention (RISE) to Improve Cancer-Related Cognitive Impairment and Gut Microbiome in Adolescent and Young Adult Brain Tumor Survivors

NCT06799481
View directory record Official record
Conditions
Cancer-related Cognitive Dysfunction, Primary Brain Neoplasm
Interventions
Aerobic Exercise, Behavioral Intervention, Follow-Up, Internet-Based Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Resistance Training
Other · Behavioral · Procedure
Lead sponsor
Emory University
Other
Eligibility
15 Years to 39 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 28, 2026, 4:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

NCT00429312
View directory record Official record
Conditions
Melanoma
Interventions
JX-594
Biological
Lead sponsor
Jennerex Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Los Angeles, California • Billings, Montana • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 28, 2026, 4:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurophysiology of Surround Inhibition in the Human Motor Cortex

NCT03018262
View directory record Official record
Conditions
Normal Physiology
Interventions
TMS - sub-study 1, TMS - sub-study 2, TMS - sub-study 3
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 28, 2026, 4:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Dietary Fiber on Fecal Microbiota and Metabolism

NCT01518088
View directory record Official record
Conditions
Focus of the Study is on Gut Health
Interventions
Dietary Fiber
Dietary Supplement
Lead sponsor
Ingredion Incorporated
Industry
Eligibility
20 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 28, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma

NCT00002501
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, cyclophosphamide
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2006
U.S. locations
15
States / cities
Chicago, Illinois • Iowa City, Iowa • Baltimore, Maryland + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 28, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults

NCT05398796
View directory record Official record
Conditions
Nipah Virus Infection
Interventions
mRNA -1215
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 28, 2026, 4:15 PM EDT
Recruiting Phase 2 Interventional

Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.

NCT07512362
View directory record Official record
Conditions
Mild Cognitive Impairment, Early Alzheimer's Disease, AD-MCI
Interventions
human Mesenchymal Stem Cells
Biological
Lead sponsor
Bernard (Barry) Baumel
Other
Eligibility
55 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 28, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects

NCT04588727
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD3366, Placebo, Ticagrelor, acetylsalicylic acid (ASA)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 28, 2026, 4:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of D-cycloserine on Extinction of Fear Conditioning

NCT00352586
View directory record Official record
Conditions
Fear
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 28, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers

NCT03301870
View directory record Official record
Conditions
Irritation Potential of Topic Agent
Interventions
ATx201 Gel 2%, ATx201 Gel 4%, Positive Control, Negative Control, ATx201 Placebo
Drug
Lead sponsor
UNION therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 28, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease

NCT03618641
View directory record Official record
Conditions
Melanoma, Lymph Node Cancer
Interventions
CMP-001, Nivolumab
Drug · Biological
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 28, 2026, 4:15 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

NCT05363605
View directory record Official record
Conditions
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations, FGFR3, FGFR3 Overexpression, FGFR3 Receptor, FGFR3 Protein Overexpression, Ovarian Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Lung Cancer, Gastric Cancer
Interventions
[225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab
Drug · Biological
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Duarte, California • San Francisco, California • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 28, 2026, 4:15 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

NCT05363631
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic
Interventions
Selenomethionine (SLM), Axitinib, Pembrolizumab
Drug
Lead sponsor
Mohammed Milhem
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 28, 2026, 4:15 PM EDT
Recruiting Phase 1 Interventional

Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

NCT06705686
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer (CRPC), Metastatic Castration-resistant Prostate Carcinoma
Interventions
(R)-9bMS
Drug
Lead sponsor
TechnoGenesys, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 28, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)

NCT00690066
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Insulin-Dependent, Juvenile Diabetes
Interventions
PROCHYMAL®, Placebo
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
12 Years to 35 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • La Jolla, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 28, 2026, 4:15 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle

NCT01266577
View directory record Official record
Conditions
Brain Mapping, Healthy Volunteer
Interventions
NSR MAGNETOM 7T, 1Tx x 32Rx Head Coil
Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 28, 2026, 4:15 PM EDT
Completed Phase 1Phase 2 Interventional

Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV

NCT01570595
View directory record Official record
Conditions
Tobacco Use Cessation, Tobacco Cessation, Tobacco Use Disorder, Tobacco Dependence, Tobacco-Use Disorder, Virus, Human Immunodeficiency
Interventions
Web-Based Tailored Smoking Cessation Intervention, Standard of Care
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 28, 2026, 4:15 PM EDT
Recruiting Not applicable Interventional

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer

NCT06106477
View directory record Official record
Conditions
Breast Cancer
Interventions
Intermittent Fasting
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 28, 2026, 4:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Steering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men

NCT02572401
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Sexually Transmitted Disease (STD)
Interventions
STAND HIV Risk Reduction Intervention, Text Messaging Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
391 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 28, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab

NCT04401995
View directory record Official record
Conditions
Melanoma
Interventions
Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
Drug · Biological · Other
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 28, 2026, 4:15 PM EDT